Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.71)
# 4,112
Out of 5,113 analysts
57
Total ratings
32.65%
Success rate
-26.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKTX Akari Therapeutics, | Initiates: Buy | $1 | $0.25 | +293.70% | 1 | Jan 5, 2026 | |
| ARDX Ardelyx | Assumes: Buy | $11 | $7.86 | +39.95% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $21.32 | +45.40% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.63 | +1,065.64% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $20.54 | +2.24% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $6.16 | -18.83% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.89 | +746.56% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $1.03 | +11,550.49% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $21.57 | +15.90% | 2 | May 14, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Neutral | n/a | $81.90 | - | 3 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,000 | $2.08 | +96,053.85% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.22 | +473.77% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.98 | +67.22% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $13.56 | +342.48% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $1.24 | +383.87% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.38 | +195.86% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $1.67 | +14,271.26% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $2.79 | +6,423.30% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $4,500 → $2,000 | $3.14 | +63,594.27% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.70 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.09 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.85 | +601.84% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $8.37 | +150.90% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $9.10 | +115,284.62% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $3.04 | +1,117.11% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $35.91 | +735.42% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $751.13 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $101.18 | -12.04% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $134.66 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $1.53 | +21,860.78% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.97 | +353.40% | 1 | Mar 19, 2020 |
Akari Therapeutics,
Jan 5, 2026
Initiates: Buy
Price Target: $1
Current: $0.25
Upside: +293.70%
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $7.86
Upside: +39.95%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $21.32
Upside: +45.40%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.63
Upside: +1,065.64%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $20.54
Upside: +2.24%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $6.16
Upside: -18.83%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.89
Upside: +746.56%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $1.03
Upside: +11,550.49%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $21.57
Upside: +15.90%
Spruce Biosciences
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $81.90
Upside: -
Feb 8, 2024
Initiates: Buy
Price Target: $2,000
Current: $2.08
Upside: +96,053.85%
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.22
Upside: +473.77%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $5.98
Upside: +67.22%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $13.56
Upside: +342.48%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $1.24
Upside: +383.87%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.38
Upside: +195.86%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $1.67
Upside: +14,271.26%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $2.79
Upside: +6,423.30%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $4,500 → $2,000
Current: $3.14
Upside: +63,594.27%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $10.70
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.09
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $0.85
Upside: +601.84%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $8.37
Upside: +150.90%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $9.10
Upside: +115,284.62%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $3.04
Upside: +1,117.11%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $35.91
Upside: +735.42%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $751.13
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $101.18
Upside: -12.04%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $134.66
Upside: -
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $1.53
Upside: +21,860.78%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $3.97
Upside: +353.40%